TotipotentRX and ThermoGenesis to Present Clinical Data at the AABB Conference

TotipotentRX and ThermoGenesis to Present Clinical Data at the AABB Conference

Presentation on AMIRST Acute Myocardial Infarction Study and Pediatric
Allogeneic Mismatched Bone Marrow Transplant Program

RANCHO CORDOVA, Calif. and LOS ANGELES, Oct. 10, 2013 (GLOBE NEWSWIRE) --
TotipotentRX Corporation and ThermoGenesis Corp. (Nasdaq:KOOL) today announced
two upcoming presentations at a pre-conference symposium of the American
Association of Blood Banks Annual Meeting in Denver, CO on Sunday, October
13^th at 1:30 pm (MDT). The first presentation will be initial results data
from TotipotentRX's 24 month case study (Pilot Safety Trial) using its stem
cell combination product AMIRST therapy in patients with acute myocardial
infarction. The second presentation will be given on the post-transplant
survival and engraftment rates of pediatric patients receiving mismatched
(allogeneic) bone marrow transplants processed with the ThermoGenesis MXP^®
MarrowXpress^® stem cell processing technology. The presentations will be
given by Kenneth Harris, Study Director and CEO of TotipotentRX.

In July 2013, ThermoGenesis and TotipotentRX entered into a definitive merger
agreement to form Cesca Therapeutics, and ThermoGenesis is planning to file
its Registration Statement on Form S-4 within three to four weeks. Upon
approval by shareholders of both companies and meeting other conditions, Cesca
Therapeutics will be a leading autologous cell therapeutics company, having
three lead therapy candidates in Phase I/II and II/III stages in
cardiovascular and orthopedic diseases.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and
manufacturing automated blood and bone marrow processing systems and companion
disposable products that enable the separation, processing and preservation of
cell and tissue therapy products. These include:

  *The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.
    
  *AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood. The MXP
    is used for the preparation of cell concentrates, including stem cells
    from bone marrow aspirates in the laboratory setting.
    
  *The Res-Q^TM 60 (Res-Q), a point-of-care system designed for the
    preparation of cell concentrates, including stem cells, from bone marrow
    aspirates and whole blood for platelet rich plasma (PRP).

Non-Solicitation

This press release and the information contained herein shall not constitute
an offer to sell, buy or exchange or the solicitation of an offer to sell, buy
or exchange any securities, nor shall there be any sale, purchase or exchange
of securities in any jurisdiction in which such offer, solicitation, sale,
purchase or exchange would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction.No offer of securities
shall be made except by means of a prospectus meeting the requirements of
Section 10 of the Securities Act of 1933, as amended.

Additional Information

In connection with the merger, ThermoGenesis intends to file a registration
statement (including a prospectus) on Form S-4 with the Securities and
Exchange Commission.Holders of ThermoGenesis common stock and TotipotentRX
Corporation common stock are urged to read the proxy
statement/prospectus/consent solicitation and any other relevant documents
when filed because they contain important information about ThermoGenesis,
TotipotentRX and the merger.A proxy statement will be sent to holders of
ThermoGenesis common stock and a prospectus/consent solicitation will be sent
to holders of TotipotentRX Corporation common stock.When filed, the proxy
statement/prospectus/consent solicitation and other documents relating to the
proposed merger can be obtained free of charge from the SEC's website at
www.sec.gov. These documents can also be obtained free of charge from
ThermoGenesis upon written request to ThermoGenesis, Investor Relations, 2711
Citrus Road Rancho Cordova, CA 95742.ThermoGenesis and its directors and
executive officers may be deemed to be participants in ThermoGenesis'
solicitation of proxies from its shareholders in connection with the proposed
merger. Information regarding the participants and their security holdings can
be found in ThermoGenesis' most recent proxy statement filed with the SEC,
which are available from the SEC, and the proxy statement/prospectus/consent
solicitation when it is filed with the SEC.

CONTACT: ThermoGenesis Corp. Investor Relations
         +1-916-858-5107, or
         ir@thermogenesis.com
         http://www.thermogenesis.com

ThermoGenesis Corp. Logo